ADEL and Oricell pre-IPO funding for oncology
ADEL raised $33 million in a pre-IPO financing following a major partnership deal with Sanofi, bolstering its oncology plans ahead of a public listing. Separately, Oricell Therapeutics closed a $110 million pre-IPO round to accelerate global development of CAR-T cell therapies targeting solid tumors, highlighting strong late-stage investor appetite for oncology platforms despite the scientific and clinical challenges of solid-tumor CAR-T. Find out more details in 5 news articles below.
ADEL Raises $33M In Pre-IPO Round After Major Sanofi Deal
Citeline - ScripApr 13, 2026Oricell raises $110M in pre-IPO round to advance solid tumor CAR Ts
BioWorld (Clarivate)Apr 10, 2026Oricell closes a ‘pre-IPO’ megaround to aim CAR-T at solid tumors
BioPharma DiveFREEApr 10, 2026Oricell raises $110M in pre-IPO round to advance solid tumor CAR Ts
BioWorld (Clarivate)Apr 10, 2026Oricell Therapeutics Closes $110 Million Pre-IPO Financing to Accelerate Global Development of Solid Tumor CAR-T Therapies
PR Newswire - HealthFREEApr 10, 2026
Want daily biotech news like this? Sign up free